Table 1.

Baseline Characteristics by Treatment Group According to Diagnostic and Risk Strata

	Placebo Total (N=95)	Triostat Total (N=98)
Gender
Female	43 (45.3%)	42 (42.9%)
Male	52 (54.7%)	56 (57.1%)
Age (mo)
N	95	98
Mean	5.8	5.3
SD	5.3	4.6
Median	4.6	5.4
25%, 75%	0.8, 7.8	1.1, 7.3
Min, Max	0.1, 23.2	0.0, 21.2
High-risk
Total	31	31
Infant CoA	2 (2.1%)	2 (2.0%)
TGA	14 (14.7%)	14 (14.3%)
HLV	5 (5.3%)	5 (5.1%)
TA PVD	3 (3.2%)	4 (4.1%)
Other high-risk	7 (7.4%)	6 (5.1%)
Low-risk
Total	64	67
Isolated VSD	21 (22.1%)	21 (21.4%)
TOF	17 (17.9%)	17 (17.3%)
CAVC	15 (15.8%)	16 (16.3%)
Other low-risk	7 (7.4%)	7 (7.1%)
SVC-PA	4 (4.2%)	6 (6.1%)

Baseline characteristics for the total population within surgical diagnostic categories are shown. There are no significant differences between Triostat and placebo cohorts for any group. The first 5 diagnostic groups are high-risk with Aristotle scores >10; the next 5 are lower-risk with score Aristotle score <10.

CAVC indicates complete atrioventricular valve repair; CoA, neonatal coarctation repair; HLV, hypoplastic left ventricle with Norwood; SVC-PA, superior vena cava to pulmonary artery shunt; TAPVD, repair of total anomalous pulmonary venous drainage and other high risk operations; TGA, transposition of great arteries with arterial switch; TOF, tetralogy of Fallot; VSD, isolated ventricular septal defect.